Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary

Aikou Okamoto, Rosalind M. Glasspool, Seiji Mabuchi, Noriomi Matsumura, Hiroyuki Nomura, Hiroaki Itamochi, Masashi Takano, Tadao Takano, Nobuyuki Susumu, Daisuke Aoki, Ikuo Konishi, Alan Covens, Jonathan Ledermann, Delia Mezzazanica, Christopher Steer, David Millan, Iain A. Mcneish, Jacobus Pfisterer, Sokbom Kang, Laurence GladieffJane Bryce, Amit Oza

Research output: Contribution to journalReview articlepeer-review

109 Citations (Scopus)


Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than highgrade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/ carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/ JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.

Original languageEnglish
Pages (from-to)S20-S25
JournalInternational Journal of Gynecological Cancer
Issue number9
Publication statusPublished - 11-2014
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology


Dive into the research topics of 'Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary'. Together they form a unique fingerprint.

Cite this